试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-19
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
编号:NCT03318861登记状态:提前终止企业 / 申办者:Kite, A Gilead Company
药物 / 成分:KITE-585、Cyclophosphamide、Fludarabine
登记的停止原因(原文):The study was terminated due to lack of efficacy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-19
Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition
编号:NCT04847921登记状态:提前终止企业 / 申办者:University of Colorado, Denver
药物 / 成分:Dalbavancin
登记的停止原因(原文):Delays in recruitment due to COVID-19 and higher than acceptable loss to followup.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-19
A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome
编号:NCT05098509登记状态:提前终止企业 / 申办者:Radius Pharmaceuticals, Inc.
药物 / 成分:RAD011、Placebo
登记的停止原因(原文):Due to a change in corporate priorities, this study was voluntarily terminated by the Sponsor for reasons other than safety
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-18
Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
编号:NCT03714555登记状态:提前终止企业 / 申办者:HonorHealth Research Institute
药物 / 成分:Safety Laboratories、AE Assessment、Physical Exam、Concomitant Medication Review
登记的停止原因(原文):Study was closed due to low subject enrollment at site.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-18
Continuous Vs Single Shot Block After ACL
编号:NCT04101682登记状态:提前终止企业 / 申办者:Northwell Health
药物 / 成分:Bupivacaine
登记的停止原因(原文):Not enough enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-18
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
编号:NCT04591808登记状态:提前终止企业 / 申办者:Institut de Recherches Internationales Servier
药物 / 成分:Atorvastatin/Perindopril、Atorvastatin、Perindopril
登记的停止原因(原文):for strategic reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-18
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
编号:NCT04739358登记状态:提前终止企业 / 申办者:Criterium, Inc.
药物 / 成分:Tepotinib
登记的停止原因(原文):Study was terminated due to lack of lack of enrollment and difficult patient population.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-17
Does Optimized General Anesthesia Care Reduce Postoperative Delirium?
编号:NCT02604459登记状态:提前终止企业 / 申办者:University of Missouri-Columbia
药物 / 成分:cerebral oximeter (Fore-Sight)、depth of anesthesia monitor (BIS)、BP management、General anesthesia
登记的停止原因(原文):Limited availability of subjects meeting inclusion criteria resulting in early termination (lack of funding) before meeting target enrollment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-17
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
编号:NCT02899728登记状态:提前终止企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Carboplatin、Cediranib、Cediranib Maleate、Cisplatin
登记的停止原因(原文):Inadequate accrual rate
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-10-17
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
编号:NCT03366103登记状态:提前终止企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Navitoclax、Vistusertib
登记的停止原因(原文):Drug supply issues
查看官方原始记录 ↗